Survodutide: The GLP-1/Glucagon Dual Agonist Redefining Metabolic Therapy
While much of the metabolic drug landscape has centered on GLP-1 and GIP receptor agonism — exemplified by semaglutide and tirzepatide — Boehringer Ingelheim has pursued a fundamentally different combination. Survodutide (BI 456906) is a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors, a pairing that was once considered counterintuitive but is now generating some of the most striking clinical data in obesity and liver disease research.
The inclusion of glucagon receptor activity sets survodutide apart from every approved GLP-1-based therapy, introducing direct hepatic effects that may make it uniquely suited for metabolic conditions rooted in liver pathology.
Why Glucagon? The Counterintuitive Target
Glucagon has historically been viewed as the metabolic antagonist of insulin — a hormone that raises blood glucose, stimulates glycogenolysis, and promotes hepatic glucose output. Activating the glucagon receptor in a metabolic drug seems, at first glance, paradoxical.
However, glucagon also plays critical roles in energy expenditure, lipid oxidation, and hepatic fat metabolism. Habegger et al., 2010 demonstrated that glucagon receptor signaling increases resting energy expenditure and promotes lipid catabolism in the liver, effects that GLP-1 agonism alone does not robustly produce.
The key insight behind survodutide is that co-agonism with GLP-1 offsets glucagon's hyperglycemic effects. GLP-1 receptor activation enhances insulin secretion in a glucose-dependent manner, effectively buffering the glucose-raising action of glucagon while preserving its beneficial effects on hepatic lipid metabolism and thermogenesis. Day et al., 2009 provided early preclinical validation of this dual-agonist concept, showing that GLP-1/glucagon co-agonists produced superior weight loss compared to selective GLP-1 agonists in rodent models.
Molecular Design and Pharmacology
Survodutide is a 39-amino-acid acylated peptide based on a modified oxyntomodulin backbone. Oxyntomodulin is an endogenous gut hormone that naturally engages both GLP-1 and glucagon receptors, though with relatively low potency at each. Survodutide was engineered by Boehringer Ingelheim and Zealand Pharma to dramatically improve receptor binding affinity, metabolic stability, and pharmacokinetic half-life.
The peptide incorporates a fatty acid side chain enabling albumin binding, which extends its circulating half-life sufficiently for once-weekly subcutaneous dosing. Its GLP-1-to-glucagon activity ratio is carefully calibrated — providing enough glucagon receptor activation to drive hepatic effects while maintaining sufficient GLP-1 activity to control glycemia and appetite.
Phase 2 Results in Obesity
The phase 2 trial in adults with overweight or obesity without diabetes produced headline-grabbing results. Blüher et al., 2024, published in the New England Journal of Medicine, reported outcomes from a 46-week randomized, placebo-controlled study of 387 participants.
Key findings at the highest evaluated dose (4.8 mg weekly) included:
These weight loss figures position survodutide competitively alongside tirzepatide and high-dose semaglutide. Importantly, the metabolic improvements observed — particularly in liver enzymes and lipid parameters — suggested effects beyond what appetite suppression alone could explain.
The MASH Opportunity: Where Survodutide May Excel
Perhaps the most compelling clinical story for survodutide lies in metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. The glucagon receptor component gives survodutide a direct mechanism for reducing hepatic steatosis that pure GLP-1 agonists lack.
The phase 2 trial in MASH patients delivered remarkable histological outcomes. Sanyal et al., 2024, published in the New England Journal of Medicine, evaluated survodutide in 293 adults with biopsy-confirmed MASH and liver fibrosis stages F1-F3 over 48 weeks.
Results included:
These numbers are striking. For context, resmetirom (Rezdiffra), the first FDA-approved drug for MASH, achieved MASH resolution in approximately 25-30% of patients in its phase 3 MAESTRO-NASH trial (Harrison et al., 2024). While cross-trial comparisons carry significant limitations, survodutide's histological response rates have generated enormous interest.
Boehringer Ingelheim has advanced survodutide into the phase 3 TRIUMPH program for MASH, with multiple trials underway including populations with compensated cirrhosis (ClinicalTrials.gov: NCT06351423).
Safety and Tolerability Profile
The tolerability profile of survodutide follows the general pattern of incretin-based therapies, though with some nuances attributable to its glucagon component.
The most common adverse events across trials were gastrointestinal in nature:
Discontinuation rates due to adverse events were dose-dependent, ranging from approximately 7-15% across dose groups in the obesity trial. The 6.0 mg arm notably had higher attrition, which led Boehringer to focus on the 4.8 mg dose as the primary target for phase 3 development.
One theoretical concern with glucagon receptor activation is hyperglycemia, but this was not observed clinically — HbA1c decreased across all survodutide dose groups in both diabetic and non-diabetic populations. Increases in heart rate, a class effect of GLP-1 receptor agonists, were observed but were modest, consistent with other agents in the class (Nauck et al., 202100203-5)).
Longer-term cardiovascular safety data remain unavailable, and the ongoing phase 3 program will be critical for characterizing the full safety profile.
Competitive Landscape and Differentiation
The metabolic therapeutics space is increasingly crowded, with multiple mechanisms under investigation:
Survodutide's closest mechanistic comparator is arguably retatrutide, which adds GIP receptor agonism on top of GLP-1 and glucagon activity. Jastreboff et al., 2023 reported weight loss of up to 24.2% at 48 weeks with retatrutide, suggesting the triple agonist approach may offer greater maximal weight reduction.
However, survodutide's differentiation may ultimately rest on its liver-specific efficacy. The glucagon receptor's dense hepatic expression gives survodutide a pharmacological rationale for MASH that GLP-1/GIP dual agonists do not inherently possess. If phase 3 MASH data confirm the phase 2 results, survodutide could become the most effective pharmaceutical intervention for liver fibrosis regression currently in development.
Ongoing Development
Boehringer Ingelheim is running multiple phase 3 programs:
Results from these pivotal trials are expected between 2026 and 2028, with potential regulatory submissions to follow if outcomes are positive.